Immunotherapy for gynaecological malignancies

George Coukos, Jose R. Conejo-Garcia, Richard S Roden, Tzyy Choou Wu

Research output: Contribution to journalArticle

Abstract

Gynaecological malignancies, excluding breast cancer, cause ∼ 25,000 deaths yearly among women in the US. Therefore, novel approaches for the prevention or treatment of these diseases are urgently required. In the case of cervical cancer, human papillomavirus (HPV) xenoantigens are readily recognised by the immune system, and their targeting has shown great promise in preclinical models of therapeutic vaccination and in clinical studies of peventative vaccination. A growing body of evidence indicates that ovarian cancer is also immunogenic and can thus be targeted through immunotherapy. This review outlines the principles and problems of immunotherapy for cervical and ovarian cancer, including the authors' personal assessment.

Original languageEnglish (US)
Pages (from-to)1193-1210
Number of pages18
JournalExpert Opinion on Biological Therapy
Volume5
Issue number9
DOIs
StatePublished - Sep 2005

Fingerprint

Heterophile Antigens
Immune system
Uterine Cervical Neoplasms
Ovarian Neoplasms
Immunotherapy
Vaccination
Immune System
Neoplasms
Breast Neoplasms
Therapeutics
Clinical Studies

Keywords

  • Cervical cancer
  • Cytokine
  • HPV
  • Immunotherapy
  • Lymphocyte
  • Ovarian cancer
  • Tumour-infiltrating
  • Vaccine development

ASJC Scopus subject areas

  • Pharmacology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Genetics
  • Immunology

Cite this

Immunotherapy for gynaecological malignancies. / Coukos, George; Conejo-Garcia, Jose R.; Roden, Richard S; Wu, Tzyy Choou.

In: Expert Opinion on Biological Therapy, Vol. 5, No. 9, 09.2005, p. 1193-1210.

Research output: Contribution to journalArticle

Coukos, George ; Conejo-Garcia, Jose R. ; Roden, Richard S ; Wu, Tzyy Choou. / Immunotherapy for gynaecological malignancies. In: Expert Opinion on Biological Therapy. 2005 ; Vol. 5, No. 9. pp. 1193-1210.
@article{b1a32c166078408ba5f19550545690ea,
title = "Immunotherapy for gynaecological malignancies",
abstract = "Gynaecological malignancies, excluding breast cancer, cause ∼ 25,000 deaths yearly among women in the US. Therefore, novel approaches for the prevention or treatment of these diseases are urgently required. In the case of cervical cancer, human papillomavirus (HPV) xenoantigens are readily recognised by the immune system, and their targeting has shown great promise in preclinical models of therapeutic vaccination and in clinical studies of peventative vaccination. A growing body of evidence indicates that ovarian cancer is also immunogenic and can thus be targeted through immunotherapy. This review outlines the principles and problems of immunotherapy for cervical and ovarian cancer, including the authors' personal assessment.",
keywords = "Cervical cancer, Cytokine, HPV, Immunotherapy, Lymphocyte, Ovarian cancer, Tumour-infiltrating, Vaccine development",
author = "George Coukos and Conejo-Garcia, {Jose R.} and Roden, {Richard S} and Wu, {Tzyy Choou}",
year = "2005",
month = "9",
doi = "10.1517/14712598.5.9.1193",
language = "English (US)",
volume = "5",
pages = "1193--1210",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - Immunotherapy for gynaecological malignancies

AU - Coukos, George

AU - Conejo-Garcia, Jose R.

AU - Roden, Richard S

AU - Wu, Tzyy Choou

PY - 2005/9

Y1 - 2005/9

N2 - Gynaecological malignancies, excluding breast cancer, cause ∼ 25,000 deaths yearly among women in the US. Therefore, novel approaches for the prevention or treatment of these diseases are urgently required. In the case of cervical cancer, human papillomavirus (HPV) xenoantigens are readily recognised by the immune system, and their targeting has shown great promise in preclinical models of therapeutic vaccination and in clinical studies of peventative vaccination. A growing body of evidence indicates that ovarian cancer is also immunogenic and can thus be targeted through immunotherapy. This review outlines the principles and problems of immunotherapy for cervical and ovarian cancer, including the authors' personal assessment.

AB - Gynaecological malignancies, excluding breast cancer, cause ∼ 25,000 deaths yearly among women in the US. Therefore, novel approaches for the prevention or treatment of these diseases are urgently required. In the case of cervical cancer, human papillomavirus (HPV) xenoantigens are readily recognised by the immune system, and their targeting has shown great promise in preclinical models of therapeutic vaccination and in clinical studies of peventative vaccination. A growing body of evidence indicates that ovarian cancer is also immunogenic and can thus be targeted through immunotherapy. This review outlines the principles and problems of immunotherapy for cervical and ovarian cancer, including the authors' personal assessment.

KW - Cervical cancer

KW - Cytokine

KW - HPV

KW - Immunotherapy

KW - Lymphocyte

KW - Ovarian cancer

KW - Tumour-infiltrating

KW - Vaccine development

UR - http://www.scopus.com/inward/record.url?scp=24144468941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24144468941&partnerID=8YFLogxK

U2 - 10.1517/14712598.5.9.1193

DO - 10.1517/14712598.5.9.1193

M3 - Article

C2 - 16120050

AN - SCOPUS:24144468941

VL - 5

SP - 1193

EP - 1210

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 9

ER -